Besifovir dipivoxil
- Generic Name
- Besifovir dipivoxil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H34N5O8P
- CAS Number
- 441785-26-8
- Unique Ingredient Identifier
- S9I9P4J8IU
- Background
Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.
- Indication
Investigated for use/treatment in hepatitis (viral, B).
- Associated Conditions
- -
- Associated Therapies
- -
A Food Effect Study of Besifovir in Healthy Subjects
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT03885778
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
Phase 4
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 76
- Registration Number
- NCT03604016
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath